| Literature DB >> 32894146 |
Chin-Yi Liao1, Timothy L Tan2, Yu-Der Lu1, Cheng-Ta Wu1, Mel S Lee1, Feng-Chih Kuo3.
Abstract
BACKGROUND: This study aimed to evaluate the effect of dipyridamole-thallium scanning (DTS) on the rates of 90-day cardiac complications and 1-year mortality in patients with a femoral neck fracture treated with hemiarthroplasty.Entities:
Keywords: Cardiac complications; Dipyridamole-thallium scanning; Femoral neck fracture; Hemiarthroplasty; Mortality
Mesh:
Substances:
Year: 2020 PMID: 32894146 PMCID: PMC7487939 DOI: 10.1186/s13018-020-01918-w
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Baseline demographic data, surgical factors, and length of stay in unmatched and matched patients who did and did not undergo a dipyridamole-thallium scan
| Non-thallium scan group | |||||
|---|---|---|---|---|---|
| Thallium scan group ( | Unmatched cohort ( | Matched cohort ( | |||
| Age, mean ± SD, years | 79.8 ± 8.3 | 74.7 ± 11.3 | < 0.001 | 79.9 ± 8.3 | 0.901 |
| Sex, | 0.590 | 0.908 | |||
| Male | 37 (32.7) | 221 (30.2) | 109 (32.2) | ||
| Female | 76 (67.3) | 510 (69.8) | 230 (67.8) | ||
| Body mass index, mean ± SD, kg/m2 | 22.6 ± 3.5 | 22.7 ± 4.1 | 0.774 | 22.5 ± 3.9 | 0.980 |
| ASA grade, | < 0.001 | 0.010 | |||
| 1 | 0 (0.0) | 11 (1.5) | 2 (0.6) | ||
| 2 | 5 (4.4) | 185 (25.3) | 57 (16.8) | ||
| 3 | 106 (93.8) | 523 (71.5) | 270 (79.6) | ||
| 4 | 1 (0.9) | 10 (1.4) | 8 (2.4) | ||
| Delay until surgery, mean ± SD, days | 7.0 ± 12.4 | 2.4 ± 3.3 | < 0.001 | 3.7 ± 4.2 | < 0.001 |
| Delay until surgery > 2 days, | 110 (97.3) | 352 (48.2) | < 0.001 | 127 (37.5) | < 0.001 |
| Preoperative comorbidities, | |||||
| Ischemic heart disease | 25 (22.1) | 56 (7.7) | < 0.001 | 47 (13.9) | 0.038 |
| CHF | 6 (5.3) | 27 (3.7) | 0.431 | 20 (5.9) | 0.816 |
| Valvular heart disease | 11 (9.7) | 18 (2.5) | 0.001 | 17 (5.0) | 0.071 |
| CVA | 11 (9.7) | 76 (10.4) | 0.829 | 34 (10.0) | 0.928 |
| Diabetes | 44 (38.9) | 216 (29.5) | 0.044 | 123 (36.3) | 0.613 |
| COPD | 13 (11.5) | 53 (7.3) | 0.117 | 31 (9.1) | 0.464 |
| RA | 1 (0.9) | 14 (1.9) | 0.440 | 3 (0.9) | 1.000 |
| Liver disease | 2 (1.8) | 37 (5.1) | 0.121 | 7 (2.1) | 1.000 |
| Renal disease | 14 (12.4) | 59 (8.1) | 0.129 | 37 (10.9) | 0.668 |
| Cancer | 4 (3.5) | 48 (6.6) | 0.213 | 12 (3.5) | 1.000 |
| Anesthesia type, | 0.071 | 0.597 | |||
| General | 94 (83.2) | 651 (89.1) | 289 (85.3) | ||
| Regional | 19 (16.8) | 80 (10.9) | 50 (14.7) | ||
| Cemented stem, | 65 (57.5) | 297 (40.6) | < 0.001 | 199 (58.7) | 0.826 |
| Time in surgical theater, mean ± SD, min | 125.9 ± 36.3 | 132.3 ± 44.5 | 0.142 | 125.5 ± 33.8 | 0.930 |
ASA American Society of Anesthesiologists, CHF congestive heart failure, CVA cerebrovascular accident, COPD chronic obstructive pulmonary disease, RA rheumatoid arthritis, SD standard deviation
Fig. 1Rates of 90-day cardiac complications, 90-day mortality, and 1-year mortality in patients who did and did not undergo a dipyridamole-thallium scan after propensity score-matching
Univariate and multivariate logistic regression models evaluating the associations of dipyridamole-thallium scan with the rates of 90-day cardiac complications, 90-day mortality, and 1-year mortality
| Outcome | Unmatched cohort | Matched cohort | ||||
|---|---|---|---|---|---|---|
| Unadjusted OR (95% CI) | Adjusted ORa (95% CI) | Adjusted ORb (95% CI) | ||||
| Overall 90-day cardiac complications | 1.86 (1.11–3.13) | 0.019 | 1.44 (0.71–2.91) | 0.309 | 1.32 (0.75–2.33) | 0.332 |
| Unstable angina | 6.52 (0.41–104) | 0.186 | 4.26 (0.12–154) | 0.429 | 3.02 (0.19–48.1) | 0.437 |
| Acute myocardial infarction | 3.28 (0.59–18.1) | 0.174 | 2.83 (0.38–21.2) | 0.310 | 3.04 (0.42–21.3) | 0.272 |
| 90-day mortality | 0.92 (0.11–7.58) | 0.941 | 9.80 (0.23–424.8) | 0.235 | 0.75 (0.08–6.71) | 0.797 |
| 1-year mortality | 1.09 (0.57–2.08) | 0.799 | 0.54 (0.24–1.20) | 0.128 | 0.62 (0.27–1.42) | 0.259 |
aAdjusted for age, sex, body mass index, American Society of Anesthesiologists (ASA) grade, preoperative comorbidities (ischemic heart disease, congestive heart failure, valvular heart disease, cerebrovascular accident, diabetes, chronic obstructive pulmonary disease, rheumatoid arthritis, liver disease, renal disease, and cancer history), surgical variables (anesthesia and cemented stem, operative duration, and transfusion), and duration to surgery
bAdjusted for ASA grade and ischemic heart disease
OR odds ratio, CI confidence interval
Results of multivariate logistic regression regarding 90-day cardiac complications
| Beta coefficient | Standard error | OR | 95% CI | ||
|---|---|---|---|---|---|
| ASA grade ≥ 3 | 1.16 | 0.41 | 3.19 | 1.44 to 7.08 | 0.004 |
| Cardiac comorbidities | 1.72 | 0.26 | 5.56 | 3.35 to 9.25 | < 0.001 |
Cardiac comorbidities included ischemic heart disease, congestive heart failure, and valvular heart disease
OR odds ratio, CI confidence interval, ASA American Society of Anesthesiologists
Results of multivariate logistic regression regarding 1-year mortality
| Beta coefficient | Standard error | OR | 95% CI | ||
|---|---|---|---|---|---|
| Delay until surgery, days | 0.14 | 0.42 | 1.15 | 1.06 to 1.25 | 0.001 |
| Age, years | 0.05 | 0.02 | 1.05 | 1.00 to 1.10 | 0.040 |
| Body mass index, kg/m2 | -0.11 | 0.05 | 0.89 | 0.81 to 0.98 | 0.015 |
| Renal disease | 1.49 | 0.49 | 4.43 | 1.71 to 11.46 | 0.002 |
OR odds ratio, CI confidence interval
Fig. 2Flowchart showing the selection process of patients and the further decision-making in the two groups, categorized according to performance of a dipyridamole-thallium scan